Transcatheter Arterial Chemoembolization for Hepatic Recurrence after Curative Resection of Pancreatic Adenocarcinoma

다국어 초록 (Multilingual Abstract)

Background/Aims: Despite curative resection, hepatic recurrences cause a significant reduction in survival in patients with primary pancreatic adenocarcinoma.
Transcatheter arterial chemoembolization (TACE) has recently been used successfully to treat primary and secondary hepatic malignancy. Methods: Between 2003 and 2008, 15 patients underwent TACE because of hepatic recurrence after curative resection of a pancreatic adenocarcinoma. The tumor response was evaluated based on computed tomography scans after TACE. The overall duration of patient survival was measured. Results: After TACE, a radiographically evident response occurred in six patients whose tumors demonstrated a tumor blush on angiography.
Four patients demonstrated stabilization of a hypovascular mass. The remaining five patients demonstrated continued progression of hypovascular hepatic lesions. The median survival periods from the time of diagnosis and from the time of initial TACE were 9.6and 7.5 months, respectively. Conclusions: TACE may represent a viable therapeutic modality in patients with hepatic recurrence after curative resection of pancreatic adenocarcinoma.

참고문헌 (Reference)

1 Bramhall SR, "Treatment and survival in 13,560 patients with pancreatic cancer, and incidence of the disease,in the west midlands: an epidemiological study" 82 : 111-115, 1995

2 Kim JH, "Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis" 29 : 1291-1298, 2009

3 Kim JH, "Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma: clinical efficacy and factors influencing outcomes" 113` : 1614-1622, 2008

4 Liapi E, "Transcatheter and ablative therapeutic approaches for solid malignancies" 25 : 978-986, 2007

5 Rajan DK, "Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization" 12 : 187-193, 2001

6 Sohn TA, "Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators" 4 : 567-579, 2000

7 Sperti C, "Recurrenceafter resection for ductal adenocarcinoma of the pancreas" 21 : 195-200, 1997

8 Westerdahl J, "Recurrence of exocrine pancreatic cancer--local or hepatic?" 40 : 384-387, 1993

9 Brown DB, "Quality improve ment guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy" 17 (17): 225-232, 2006

10 Cleary SP, "Prognostic factors in resected pancreatic adenocarcinoma: analysis of actual 5-year survivors" 198 : 722-731, 2004

11 Park YS, "Primary hepatic angiosarcoma: imaging findings and palliative treatment with transcatheter arterial chemoembolization or embolization" 64 : 779-785, 2009

12 Hishinuma S, "Patterns of recurrence after curative resection of pancreatic cancer, based on autopsy findings" 1p : 511-518, 2006

13 Griffin JF, "Patterns of failure after curative resection of pancreatic carcinoma" 66 : 56-61, 1990

14 Sener SF, "Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database" 189 : 1-7, 1999

15 Matsuno S, "Pancreatic Cancer Registry in Japan: 20 years of experience" 28 : 219-230, 2004

16 Kim JH, "Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization" 255 : 270-277, 2010

17 Lencioni R, "Modified RECIST (mRECIST) assessment for hepatocellular carcinoma" 30 : 52-60, 2010

18 Richter A, "Lorenz D, Post S, Trede M. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience" 27 : 324-329, 2003

19 Nitecki SS, "Longterm survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?" 221 : 59-66, 1995

20 Katsumata K, "Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres" 8 : 110-112, 2003

21 Song SY, "Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome" 12 : 313-320, 2001

22 Burris HA 3rd, "Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer:a randomized trial" 15 : 2403-2413, 1997

23 Noda A, "Hypervascular liver metastasis from hypovascular ductal cell carcinoma of thepancreas" 40 : 227-231, 2001

24 Jakobs TF, "Hepatic yttrium-90 radioembolization of chemotherapy-refractory colorectal cancer liver metastases" 19 : 1187-1195, 2008

25 Ruutiainen AT, "Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver" 18 : 847-855, 2007

26 Tepper J, "Carcinoma of the pancreas: reviewof MGH experience from 1963 to 1973. Analysis of surgical failure and implications for radiation therapy" 37 : 1519-1524, 1976

27 Jemal A, "Cancer statistics, 2007" 57 : 43-66, 2007

28 Buijs M, "Assessment of metastatic breast cancer response to chemoembolization with contrast agent enhanced and diffusion-weighted MR imaging" 18 : 957-963, 2007

29 Murphy-Lavallee J, "Are metastases really hypovascular in the arterial phase? The perspective based on contrast-enhanced ultrasonography" 26 : 1545-1556, 2007